Viral Safety by Design for Cell and Gene Therapy Products

Presented by

Mark Plavsic, Chief Technology Officer at Lysogene & Dr. Magali Roche, Sales Manager, PathoQuest, Biologics Genomic Service

About this talk

Presented by Mark Plavsic, Chief Technology Officer at Lysogene Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C&GT) biologics. Adventitious agents (viruses, bacteria, mycoplasma, prions, etc) pose constant risk to these biologics, and, as such they may impact directly product and patient safety. It is therefore of supreme importance to intentionally (by design) employ effective measures across the whole C&GT product manufacturing process to mitigate risk of adventitious agents. This presentation will review various interconnected steps throughout the manufacturing process, from the raw materials to the fill and finish, that would, in concert, help mitigate the risk while providing a high degree of product safety by design. FOLLOWED BY NEXT-GENERATION SEQUENCING FOR FAST AND PERFORMANT RESULTS APPLIED TO CELL AND GENE THERAPY PRODUCTS. Presented by Dr. Magali Roche, Sales Manager, PathoQuest, Biologics Genomic Service

Related topics:

More from this channel

Upcoming talks (17)
On-demand talks (243)
Subscribers (24807)
BioPharma Webinars aims to keep its 30,000 readers abreast of all developments in the areas of Drug Development, Drug Delivery, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality articles, written by the most respected authors, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.